Testing two doses of a new lung scarring treatment

Plain-English translation of NCT07516951 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a new medication called zampilimab to see if it can help people with idiopathic pulmonary fibrosis (a disease where lung tissue becomes scarred and stiff, making it hard to breathe). Researchers want to find out which of two doses works best and is safest. About 240 people will participate, with some receiving the medication and others receiving a placebo (a dummy treatment) to compare results fairly.

Idiopathic pulmonary fibrosis is a serious lung disease with limited treatment options, and existing treatments don't work for everyone. This trial exists to see whether this new treatment can help slow or stop the scarring and help patients breathe better.

Do you qualify?

You likely qualify if…

you are at least 40 years old and expected to live at least one more year
you have been diagnosed with idiopathic pulmonary fibrosis within the past 8 years
your lung function tests show your lungs still have at least 45% of normal capacity
your oxygen levels are reasonably stable (above 90% at rest with modest oxygen support)
you weigh at least 45 kilograms (about 99 pounds)

You likely don't qualify if…

you have had a serious lung infection or sudden worsening of your breathing in the last 4 weeks
you have a history of lung cancer or active cancer diagnosis
you are currently taking strong immunosuppressant or chemotherapy drugs, or have taken them in the last year
you have emphysema that is very severe or more extensive than the lung scarring
you have other serious medical conditions (heart, kidney, liver, or infections like tuberculosis) that are not well controlled

What participation looks like

If you join, you'll be randomly assigned to receive either one of two doses of the new medication or a placebo, and you won't know which you're getting. You'll visit the research center multiple times over 24 weeks (about 6 months), where doctors will check your lung function, oxygen levels, and overall health. You'll also have imaging scans and blood tests to monitor how the treatment is working and watch for any side effects.

AI-generated summary from trial data · Jul 20, 2026 · Not medical advice

Trial locations(1 site)

North Macedonia

PHI University Clinic of Pulmonology and Allergology, Skopje